

UNIV.-PROF. DR. MED. STAVROS KONSTANTINIDES, FESC, FRCP(Glasg)

Aktuelle Position	Professur Multizentrische Klinische Studien und Medizinischer Direktor, Centrum für Thrombose und Hämostase, Universitätsmedizin Mainz Langenbeckstr. 1, Geb. 403, 55131 Mainz Tel.: +49 6131 17 8382, e-mail: stavros.konstantinides@unimedizin-mainz.de
Beruflicher und akademischer Werdegang	2018–heute: W3- Professur für Multizentrische Klinische Studien, Centrum für Thrombose und Hämostase, Universitätsmedizin Mainz 2014–heute: Medizinischer Direktor, Centrum für Thrombose und Hämostase 2009–heute: Universitätsprofessor für Kardiologie, Demokritus-Universität von Thrakien, Griechenland 2004: Zusätzliche Weiterbildung Spezielle Internistische Intensivmedizin 2003 – 2009: Apl. Professor für Innere Medizin und Leitender Oberarzt der Abteilung Kardiologie und Pneumologie, Universitätsmedizin Göttingen 2000-2002: Umhabilitation an die Georg-August-Universität Göttingen, Oberarzt der Abteilung Kardiologie und Pneumologie, Universitätsmedizin Göttingen 1999–2000: Forschungsaufenthalt bei David J. Loskutoff, Ph.D., Department of Vascular Biology, The Scripps Research Institute, La Jolla, California, USA 1998-1999: Oberarzt, Abt. Kardiologie und Pneumologie, Univ.-Medizin Göttingen 1998: Anerkennung der Schwerpunktbezeichnung Kardiologie 1998: Habilitation und Erlangung der <i>venia legendi</i> für das Fach Innere Medizin, Albert-Ludwigs-Universität Freiburg 1997: Anerkennung als Facharzt für Innere Medizin 1991-1993: Dissertation an der Albert-Ludwigs-Universität Freiburg: “Surgical Closure vs. Medical Treatment of Atrial Septal Defect in Adults: Long-Term Follow-up”; Note: <i>magna cum laude</i> (publ. im <i>New England Journal of Medicine</i> 1995) 1990-1997: Assistenzarzt und wissenschaftlicher Mitarbeiter, Abteilung Kardiologie und Angiologie, Albert-Ludwigs-Universität Freiburg 1988-1990: Wehrdienst als Offizier des Sanitätskorps (Griechenland) 1982-1987: Medizinstudium, Aristoteles-Universität Thessaloniki, Griechenland
Auszeichnungen	2019: Visiting Professor, University of Belgrade, Serbia 2017: Theodor Naegeli-Preis für Thromboseforschung, Switzerland 2017: Jaap de Graeff Medal, Leiden University Medical Center, The Netherlands 2015: Honorary Fellow, Royal College of Physicians & Surgeons of Glasgow 2015: Honorary Fellow, Romanian Society of Cardiology 2004: Novartis Foundation Prize 2001: William Harvey Prize, International Society on Thrombosis & Haemostasis
Publikationen	Scopus: publications 417; citations 28,025; h-index 70 Google Scholar: publications 536; citations 38,733; h-index 81 Ausgewählte Publikationen: • Klok FA, Toenges G, [...], Konstantinides SV. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2). <i>Lancet Haematol</i> 2021;8(9): e627-e636 • Hobohm L, Kölmel S, Niemann C, [...], Konstantinides SV, Schäfer K, Lankeit M. Role of angiopoietin-2 in venous thrombus resolution and chronic thromboembolic disease. <i>Eur Respir J</i> 2021;58(6). doi: 10.1183/13993003.04196-2020 • Barco S, Mahmoudpour SH, [...], Konstantinides SV. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. <i>Lancet Respir Med</i> 2020;8:277-287. • Barco S, Schmidtman I, [...], Wild PS, Konstantinides SV, Lankeit M; HoT-PE Investigators. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre clinical trial. <i>Eur Heart J</i> 2020;41:509-518. • Bochenek ML, Leidinger C, Rosinus NS, [...], Konstantinides S, Schäfer K. Activated endothelial TGFβ1 signaling promotes venous thrombus nonresolution in mice via endothelin-1: Potential role for chronic

thromboembolic pulmonary hypertension. *Circ Res* 2020;126(2):162-181

- Keller K, Hobohm L, [...], **Konstantinides SV**, Lankeit M. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. *Eur Heart J* 2020;41:522-529.
- Tziakas DN, Chalikias G, [...], **Konstantinides SV**, Schäfer K. Lysed erythrocyte membranes promote vascular calcification: possible role of erythrocyte-derived nitric oxide. *Circulation* 2019;139(17):2032-2048.
- Barco S, [...], **Konstantinides SV**, Meyer G. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. *Eur Heart J* 2019;40:902-910.
- **Konstantinides S**, Vicaut E, Danays T, [...], Meyer G. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. *J Am Coll Cardiol* 2017;69(12):1536-1544.
- Meyer G, Vicaut E, [...], **Konstantinides S**. Fibrinolysis for patients with acute intermediate-risk pulmonary embolism. *N Engl J Med* 2014;370: 1402-1411.
- Verhoef TJ, Ragia G, de Boer A, **Konstantinides S**, et al; the EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. *N Engl J Med* 2013;369(24):2304-2312

Leitung multizentrischer klinischer Studien

- Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban (**HoT-PE**). EudraCT No. 2013-001657-28 (completed; published *Eur Heart J* 2020 and *Eur Respir J* 2021)
- Pulmonary Embolism International Trial (**PEITHO**)-2 - A prospective, multicenter, single-arm management study to investigate the safety and efficacy of low molecular weight heparin for at least 72 hours followed by dabigatran for the treatment of acute intermediate-risk pulmonary embolism (published *Lancet Haematol* 2021).
- Pulmonary Embolism International Thrombolysis Trial (**PEITHO**) - A prospective, randomised, double-blind, placebo-controlled, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and evidence of right ventricular dysfunction. (published *N Engl J Med* 2014 and *J Am Coll Cardiol* 2017)
- **TAO** - Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (published *JAMA* 2013)
- Management Strategies and Prognosis of Pulmonary Embolism (**MAPPET**) - 3 – A multicentre double-blind randomised trial comparing alteplase with heparin alone in normotensive patients with evidence of right ventricular dysfunction or pressure overload (published *N Engl J Med* 2002)

Drittmitelein- werbung

- **DFG** Clinical Trials Programme 2020- (KO1939/3-1): PEITHO-III Studie
- **BMBF** 2012-2015 and 2015-2020 (01EO1003 & 01EO1503): Aufbau der Professur Klinische Studien, CTH, Universitätsmedizin Mainz
- **Boehringer Ingelheim** 2015-2018: PEITHO-2 Studie
- **Bayer AG**, 2014-2019: Institutional support of the academic HoT-PE trial
- **BMBF** Clinical Trials Programme (01KG0802): Multinational PEITHO trial

Internationale Kooperationen

1) Prof. Walter Ageno, University of Insubria, Italy, 2) Prof. Samuel Z. Goldhaber, Harvard Medical School, Boston, MA, USA, 3) Prof. Ander Cohen and Prof. Berverley Hunt, Guy's and St. Thomas' Trust, London, UK, 4) Prof. Menno V. Huisman, Leiden University, The Netherlands, 5) Prof. Irene Lang, Medical University of Vienna, Austria, 6) Prof. Marion Delcroix, University of Leuven, Belgium, 7) Prof. Marc Righini, Geneva University, Switzerland, 8) Prof. Nils Kucher, University of Zurich, Switzerland, 9) Prof. David Jiménez, Ramon y Cajal Hospital, Madrid, Spain, 10) Prof. Piotr Pruszczyk, Medical University of Warsaw, Poland, 11) Prof. Antoniu Petris, University of Iași, Romania, 12) Prof. Branislav Stefanovic, University of Belgrade, Serbia